(172 days)
Not Found
No
The summary describes automated arrhythmia detection algorithms but does not mention the use of AI or ML techniques in their implementation. The performance studies focus on the accuracy of the detection algorithms and physical device characteristics, not on the training or validation of AI/ML models.
No.
The device is described as an "implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG". Its primary functions are to monitor and record cardiac events and arrhythmias, not to treat them.
Yes
The device is designed to monitor and record cardiac events, such as arrhythmias, and provide diagnostic information to help identify the presence or absence of cardiac conditions like atrial fibrillation. The "Intended Use / Indications for Use" section explicitly states its purpose is for "monitoring system that records subcutaneous ECG" and is "indicated in the following cases: Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias. Patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia." This clearly indicates its role in diagnosing cardiac issues.
No
The device description clearly outlines hardware components including an implantable device (Reveal LINQ ICM), implant tools (Incision Tool, Insertion Tool), and a hand-held telemetry device (Reveal Patient Assistant).
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze samples taken from the body. The Reveal LINQ Insertable Cardiac Monitor is an implantable device that records subcutaneous ECG within the patient's body. It does not analyze samples like blood, urine, or tissue.
- The device monitors physiological signals. The primary function is to record and detect cardiac arrhythmias based on electrical signals from the heart, not to perform tests on biological specimens.
The device is a medical device for monitoring physiological parameters, specifically cardiac activity.
N/A
Intended Use / Indications for Use
The Reveal LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias.
- Patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.
The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management features in the Reveal LINQ ICM to initiate recording of cardiac event data in the implanted device memory.
Product codes
DSI
Device Description
The Reveal LINQ Model LNQ11 Insertable Cardiac Monitors (ICM) is designed to automatically record the occurrence of arrhythmias in a patient. Arrhythmia may be classified as atrial tachyarrhythmia/atrial fibrillation (AT/AF), bradyarrhythmia, pause, or (fast) ventricular tachyarrhythmia. The Reveal LINQ ICM provides storage of ECG and Marker Channel during patient-activated and automatically-detected (auto-activated) events. Auto activation may help to detect abnormal heart rhythms in patients who may not activate/trigger the ICM.
The Reveal LINO model LNO11 is a small, leadless device that is typically implanted under the skin, in the chest. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG.
A set of tools are provided with the Reveal LINQ ICM to create the small incision in the skin and to easily form a tight pocket and insert the ICM into the shallow subcutaneous pocket. There are two implant tools: the Incision Tool, used to make a small incision through the patient's skin; and the Insertion Tool, used to insert the device through the incision and into the patient's body at the desired location.
The Reveal Patient Assistant Model 9538 is a hand-held, battery-operated telemetry devices The Patient Assistant activates the data management features in the Reveal LINQ ICM to initiate recording of cardiac event data in the implanted device memory.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
chest
Indicated Patient Age Range
Not Found
Intended User / Care Setting
unsupervised patient use away from a hospital or clinic.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
XPECT Trial
Type: Validation
Follow-up: 46 hours
Sample: N = 247
Device: Reveal XT
Primary Objectives: To assess whether the AF detection algorithm reliably detected the presence or absence of AF. The XPECT trial utilized a specialized Holter to record the accuracy of the AF algorithm.
Results: The sensitivity, specificity, positive predictive value, and negative predictive value for identifying patients with any AF were 96.1%, 85.4%, 79.3%, and 97.4%, respectively. Overall accuracy reported for detecting AF was 98.5% for the Reveal XT ICM.
AIM Study
Type: Prospective, multicenter, feasibility
Follow-Up: Acute
Sample: N= 41
Device: Reveal LINQ Profile Force Probe
Primary Objectives: To characterize the insertion force based on various disease states and body types.
Results: The insertion force of a medical device implant is higher in males than females and may exceed the limit of 5 pounds of force. This data contributed to development of Insertion Tool.
MapReveal
Type: Prospective, multicenter, feasibility
Follow-up: 24 hours to > 1 month
Sample: N = 42
Device: Reveal DX/XT
Primary Objectives: To assess the signal amplitude at the recommended location of V2V3, 45 degrees. This study was designed to collect 24 hour ambulatory surface ECG mapping data and acute subcutaneous ECG data with electrode spacing shorter than that of the Reveal DX/XT devices.
Results: The recommended location offered acceptable R-wave amplitude when selected without mapping.
Subcutaneous Implant Migration (SubQ-IM)
Type: Prospective, multicenter, randomized feasibility
Follow-up: 12 weeks
Sample: N= 40 healthy volunteers (1 or 2 nonfunctional device prototypes)
Device: Reveal LINQ Nonfunctional Prototype
Primary Objectives: To observe and quantify prototype migration, or lack thereof, as well as the force of device insertion.
Results: Using fluoroscopy imaging, results of this study indicated that no significant migration occurred for a device of identical weight and shape of the Reveal LINQ device. Additionally, data regarding the force measurements contributed to the development of the Insertion Tool and Subcutaneous ECG measurements contributed to the recommended "Good" and "Best" Locations.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
XPECT Trial: The sensitivity, specificity, positive predictive value, and negative predictive value for identifying patients with any AF were 96.1%, 85.4%, 79.3%, and 97.4%, respectively. Overall accuracy reported for detecting AF was 98.5% for the Reveal XT ICM.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
510(k) Summary
| Date Prepared: | 15 August 2013 |
|---|---|
| Submitter: | Medtronic, Inc. |
| Cardiac Rhythm Disease Management | |
| 8200 Coral Sea Street NE | |
| Mounds View, MN 55112 | |
| Contact: | Eric Kalmes |
| Principal Regulatory Affairs Specialist | |
| Telephone: | (763)526-2809 |
| Fax: | (651)367-0603 |
| E-mail: | eric.b.kalmes@medtronic.com |
| Proprietary Name: | Reveal LINQTM Insertable Cardiac Monitor, |
| Model LNQ11 | |
| Reveal Patient Assistant 9538 | |
| Common Name: | Arrhythmia detector and alarm |
| Device Classification | Class II, 21 CFR 870.1025, Arrhythmia |
| detector and alarm | |
| Product Code: | DSI |
Summary of Substantial Equivalence
The intended use, design, materials and performance of the Reveal LINO ICM (Model LNQ) I ) and Reveal Patient Assistant (Model 9538) are substantially equivalent to the following predicate devices:
- The Reveal XT (Model 9529) and Reyeal DX (Model 9528) were initially cleared via . separate 510/k) applications, reference numbers K071655 on November 21, 2007. The Reveal XT (Model 9529) and Reveal DX (Model 9528) most recent modifications submission were cleared via K103764 on May 4, 2011.
- Instromedix King of Hearts Express AF Recorder K020825, Cleared April 5,2002 .
Device Description
The Reveal LINQ Model LNQ11 Insertable Cardiac Monitors (ICM) is designed to automatically record the occurrence of arrhythmias in a patient. Arrhythmia may be classified as atrial tachyarrhythmia/atrial fibrillation (AT/AF), bradyarrhythmia, pause, or (fast) ventrioular tachyarrhythmia. The Reveal LINQ ICM provides storage of ECG and Marker Channel during patient-activated and automatically-detected (auto-activated) events. Auto activation may help to detect abnormal heart rhythms in patients who may not activate/trigger the ICM.
1
The Reveal LINO model LNO11 is a small, leadless device that is typically implanted under the skin, in the chest. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG.
A set of tools are provided with the Reveal LINQ ICM to create the small incision in the skin and to easily form a tight pocket and insert the ICM into the shallow subcutaneous pocket. There are two implant tools: the Incision Tool, used to make a small incision through the patient's skin; and the Insertion Tool, used to insert the device through the incision and into the patient's body at the desired location.
The Reveal Patient Assistant Model 9538 is a hand-held, battery-operated telemetry devices The Patient Assistant activates the data management features in the Reveal LINQ ICM to initiate recording of cardiac event data in the implanted device memory.
Indications for Use
There are no changes to the Indications for Use. The Indications for Use are provided below:
The Reveal LINO Insertable Cardiac Monitors is an implantable patient-activated and automatically-activated monitoring system that record subcutaneous ECG and are indicated in the following cases:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias .
- . Patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.
The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management features in the Reveal LINQ ICM to initiate recording of cardiac event data in the implanted device memory.
Technological Characteristics
Intended use, design, materials, performance and technological characteristics are substantially equivalent to the predicate devices referenced.
Summary of Testing
Device system verification and validation testing was performed to demonstrate the Reveal LINO Model LNO11 Insertable Cardiac Monitor and its accessories meet established performance criteria to support equivalency to the reference predicate devices.
In addition the following testing was completed Reveal LINQ ICM Model LNQ11 :
Performance Testing - Bench
- Electromagnetic compatibility (EMC) .
- . Electrical safety
- Firmware and Hardware verification .
- Mechanical Verification .
- . Implant Tools Verification
2
- Packaging Design Verification .
- . Sterilization
- Biocompatibility ●
- . MRI compatibility
- Sensing and Detection performance validation .
- System Validation .
- Only the labeling changed to support Reveal LINQ ICM for the Reveal Patient Assistant . Model 9538, therefore no performance testing was completed on the 9538 Patient Assistant.
Performance Testing – Animal
- Reveal LINQ GLP Study .
Performance Testing - Clinical
The following table summarizes the clinical studies that support the incremental features and labeling of LINQ:
| Study Name /
| Number | Design | Primary Objectives | Results |
|---|---|---|---|
| XPECT Trial | Type: Validation |
Follow-up: 46 hours
Sample: N = 247
Device: Reveal XT | To assess whether the AF detection
algorithm reliably detected the
presence or absence of AF.
The XPECT trial utilized a
specialized Holter to record the
accuracy of the AF algorithm. | The sensitivity, specificity, positive
predictive value, and negative
predictive value for identifying
patients with any AF were 96.1%,
85.4%, 79.3%, and 97.4%,
respectively. Overall accuracy
reported for detecting AF was 98.5%
for the Reveal XT ICM.12 |
| AIM Study | Type: Prospective, multicenter,
feasibility
Follow-Up: Acute
Sample: N= 41
Device: Reveal LINQ Profile
Force Probe | To characterize the insertion force
based on various disease states and
body types. | The insertion force of a medical
device implant is higher in males than
females and may exceed the limit of 5
pounds of force. This data contributed
to development of Insertion Tool. |
| MapReveal | Type: Prospective, multicenter,
feasibility
Follow-up: 24 hours to > 1 month
Sample: N = 42
Device: Reveal DX/XT | To assess the signal amplitude at the
recommended location of V2V3, 45
degrees. This study was designed to
collect 24 hour ambulatory surface
ECG mapping data and acute
subcutaneous ECG data with
electrode spacing shorter than that of
the Reveal DX/XT devices. | The recommended location offered
acceptable R-wave amplitude when
selected without mapping. |
| Subcutaneous
Implant
Migration
(SubQ-IM) | Type: Prospective, multicenter,
randomized feasibility
Follow-up: 12 weeks
Sample: N= 40 healthy
volunteers (1 or 2 nonfunctional
device prototypes) | To observe and quantify prototype
migration, or lack thereof, as well as
the force of device insertion. | Using fluoroscopy imaging, results of
this study indicated that no significant
migration occurred for a device of
identical weight and shape of the
Reveal LINQ device. Additionally,
data regarding the force measurements
contributed to the development of the
Insertion Tool and Subcutaneous ECG
measurements contributed to the |
Table 1: Study Summaries
3
| Study Name /
| Number | Design | Primary Objectives | Results |
|---|---|---|---|
| Device: Reveal LINQ | |||
| Nonfunctional Prototype | recommended "Good" and "Best" | ||
| Locations. |
Performance Testing - Human Factors
- Formative and Validation Testing .
The following standards were used for bench testing; Sterilization testing; Software testing; Electromagnetic Compatibility and Electrical Safety testing; and Biocompatibility testing:
| Standard | |
|---|---|
| 1 | AAMI / ANSI / IEC 62366:2007/2008 Medical devices - Application of usability engineering to |
| medical devices | |
| 2 | ISO 10993-1:2010 (Forth Edition) Biological evaluation of medical devices - Part 1: Evaluation |
| and testing within a risk management process | |
| 3 | ISO 10993-7:2008 (Second Edition) Biological evaluation of medical devices - Part 7: Ethylene |
| oxide sterilization residuals | |
| 4 | EN 45502-1:2003 Active implantable medical devices - Part 1: General requirements for safety, |
| marking and information to be provided by the manufacturer | |
| 5 | ISO 11135-1:2007 (First Edition)Sterilization of health care products - Ethylene oxide - Part 1: |
| Requirements for development, validation and routine control of a sterilization process for medical | |
| devices | |
| 6 | EN ISO 11607-1:2009 Packaging for terminally sterilized medical devices - Part 1: Requirements |
| for materials, sterile barrier systems and packaging systems | |
| 7 | ISO 14971: 2007 (Second Edition) Medical devices - Applications of risk management to medical |
| devices | |
| 8 | IEC EN 62304: 2006/AC: 2008 Medical device software - Software life-cycle processes |
| 9 | EN 556-1:2001 Sterilization of medical devices - Requirements for medical devices to be |
| designated "STERILE" - Part 1: Requirements for terminally sterilized medical devices. | |
| 10 | IEC 60068-2-27:2008 Environmental testing - Part 2-27: Tests - Test Ea and guidance: Shock |
| 11 | ISO 14708-1:2000 Implants for surgery -- Active implantable medical devices -- Part 1: General |
| requirements for safety, marking and for information to be provided by the manufacturer | |
| 12 | ISO/TS 10974:2012 Assessment of the safety of magnetic resonance imaging for patients with an |
| active implantable medical device |
The results of the testing indicate that the Reveal LINQ ICM Model LNQ11, implant tools and Reveal Patient Assistant Model 9538 perform as intended and are safe and effective for their intended use.
Reveal Patient Assistant Model 9538 Performance Testing
Only the labeling changed for the Reveal Patient Assistant Model 9538, therefore no performance testing was completed on the 9538 Patient Assistant.
4
The results of the testing indicate that the Reveal LINQ Insertable Cardiac Monitor Model LNQ11, implant tools and Reveal Patient Assistant Model 9538 perform as intended and are safe for their intended use.
Conclusion
Medtronic has demonstrated that the Reveal LINQ device described in this submission result in a substantially equivalent device because the fundamental scientific principle, operating principle, design features and intended use are unchanged from the predicate device(s).
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle or other bird-like figure with three stylized lines representing its wings or feathers.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 14, 2014
Medtronic, Inc. Eric Kalmes Principal Regulatory Affairs Specialist 8200 Coral Sea Street, MVS11 Mounds View, MN 55112
Re: K132649
Trade/Device Name: Reveal LINQ Insertable Cardiac Monitor (ICM) model LNQ11, Reveal Patient Assistant Model 9538, and Implant Tools Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector And Alarm Regulatory Class: Class II Product Code: DSI Dated: February 10 2014 Received: February 11. 2014
Dear Mr. Eric Kalmes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilsting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
6
Page 2 - Mr. Eric Kalmes
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Image /page/6/Picture/8 description: The image contains the text "Owen Piperis -S". The text is written in a simple, sans-serif font. The word "Owen" is followed by the name "Piperis" which is stylized with some decorative elements around the letters. The last letter is followed by a hyphen and the letter "S".
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Indications For Use
510(k) Number (if known): K132649
Device Name: Reveal LINQ™ Insertable Cardiac Monitor and Reveal XT Patient Assistant
Indications for Use:
The Reveal LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:
- � Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- . Patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain that may suggest a cardiac arrhythmia.
The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management features in the Reveal LINQ ICM to initiate recording of cardiac event data in the implanted device тетогу.
Prescription Use
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)